Clotrimazole is a broad-spectrum synthetic imidazole antifungal agent used topically. It is a first-line treatment for superficial fungal infections caused by dermatophytes, yeasts (Candida), and Malassezia species. In the 1% w/v concentration, it is primarily formulated as a topical solution, cream, lotion, or spray for cutaneous application. It acts by inhibiting ergosterol synthesis, a critical component of fungal cell membranes, leading to increased membrane permeability and cell death.
Adult: Apply a thin layer to the affected and surrounding skin area twice daily (morning and evening). For Pityriasis versicolor, once daily application may be sufficient.
Note: 1. Wash and dry the affected area thoroughly. 2. Apply a sufficient amount to cover the affected area and about 1 inch of the surrounding healthy skin. 3. Gently massage until absorbed. 4. Wash hands before and after application (unless hands are the treatment site). 5. For intertriginous areas (skin folds), apply sparingly. 6. Continue use for at least 2 weeks or for at least 1 week after symptoms have cleared to prevent recurrence.
Clotrimazole is a fungistatic and fungicidal agent. Its primary mechanism is the inhibition of the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase. This enzyme is crucial for converting lanosterol to ergosterol, the main sterol component of fungal cell membranes.
Pregnancy: Pregnancy Category B (US FDA). Topical clotrimazole is considered safe during pregnancy as systemic absorption is minimal. Widely used for vulvovaginal candidiasis. However, use should be limited to necessary circumstances and under medical advice.
Driving: No effect on ability to drive or operate machinery.
| Amphotericin B | Potential antagonism of antifungal effect; concurrent use is generally not recommended. | Moderate |
| Other topical corticosteroids (e.g., Betamethasone, Clobetasol) in combination products | Combination may mask signs of infection or cause skin atrophy with prolonged use. Use fixed-dose combinations (e.g., Clobetasol + Clotrimazole) only under strict medical supervision for specified durations. | Moderate |
| Tacrolimus, Pimecrolimus (topical calcineurin inhibitors) | Theoretical risk of increased local immunosuppression; sequential use should be monitored. | Low |